InMed Historical Financial Ratios
| INM Stock | USD 5.26 0.11 2.14% |
InMed Pharmaceuticals is lately reporting on over 88 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 36.24 or Invested Capital of 1.2 M will help investors to properly organize and evaluate InMed Pharmaceuticals financial condition quickly.
InMed |
About InMed Financial Ratios Analysis
InMed PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate InMed Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on InMed financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across InMed Pharmaceuticals history.
InMed Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing InMed Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on InMed Pharmaceuticals sales, a figure that is much harder to manipulate than other InMed Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Roic
Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.Most ratios from InMed Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Research And Ddevelopement To Revenue is very stable compared to the past year. As of the 15th of December 2024, Capex To Revenue is likely to grow to 0.01, while PTB Ratio is likely to drop (7.61).
| 2022 | 2023 | 2024 (projected) | Graham Number | 18.99 | 5.26 | 208.7 | Receivables Turnover | 15.88 | 13.03 | 10.07 |
InMed Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
InMed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
InMed Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 157.61 | 58.2 | 14.52 | 3.75 | 4.14 | (7.61) | |
| Book Value Per Share | 26.57 | 27.32 | 16.19 | 4.94 | 1.21 | (17.32) | |
| Free Cash Flow Yield | (0.005756) | (0.008179) | (0.0228) | (0.16) | (0.18) | (0.28) | |
| Operating Cash Flow Per Share | (34.05) | (36.26) | (27.79) | (2.97) | (0.92) | (35.6) | |
| Pb Ratio | 157.61 | 58.2 | 14.52 | 3.75 | 4.14 | (7.61) | |
| Free Cash Flow Per Share | (34.25) | (36.27) | (27.86) | (3.04) | (0.92) | (36.74) | |
| Roic | (1.48) | (1.39) | (1.9) | (677.44) | 11.72 | 12.31 | |
| Inventory Turnover | (199.11) | (2.06E-4) | 0.22 | 1.69 | 2.81 | 109.53 | |
| Net Income Per Share | (42.57) | (37.78) | (33.17) | (3.25) | (1.01) | (111.76) | |
| Days Of Inventory On Hand | (1.83) | (1.8M) | 1.7K | 215.91 | 129.88 | 3.33 | |
| Payables Turnover | 0.19 | 0.25 | 0.47 | 5.02 | 5.58 | 2.68 | |
| Average Inventory | (748.14) | (1.2K) | (477.9M) | 60.7K | 69.8K | 73.3K | |
| Cash Per Share | 27.79 | 27.44 | 11.1 | 21.78 | 6.54 | 1.06 | |
| Pocfratio | (122.98) | (43.85) | (8.46) | (6.23) | (5.46) | (3.7) | |
| Capex To Operating Cash Flow | (0.005852) | (1.76E-4) | (0.00251) | (0.0222) | (0.00133) | (0.0319) | |
| Pfcf Ratio | (122.27) | (43.84) | (8.43) | (6.1) | (5.45) | (3.59) | |
| Days Payables Outstanding | 1.9K | 1.4K | 779.67 | 72.69 | 65.36 | 136.11 | |
| Income Quality | 0.55 | 0.66 | 0.82 | 0.96 | 0.91 | 0.32 | |
| Roe | (1.6) | (1.38) | (2.05) | (0.66) | (0.83) | 6.45 | |
| Ev To Operating Cash Flow | (122.22) | (43.12) | (8.11) | (5.06) | (4.66) | (3.96) | |
| Pe Ratio | (98.38) | (42.09) | (7.08) | (5.71) | (4.97) | (1.18) | |
| Return On Tangible Assets | (1.33) | (1.17) | (1.74) | (0.65) | (0.76) | (4.61) | |
| Ev To Free Cash Flow | (121.51) | (43.12) | (8.09) | (4.95) | (4.65) | (3.83) | |
| Earnings Yield | (0.008591) | (0.0102) | (0.0238) | (0.18) | (0.2) | (0.85) | |
| Intangibles To Total Assets | 0.0454 | 0.0599 | 0.11 | 0.14 | 0.15 | 0.4 | |
| Net Debt To E B I T D A | 0.96 | 0.64 | 0.72 | 0.31 | 0.79 | (0.13) | |
| Current Ratio | 3.77 | 3.78 | 2.89 | 5.66 | 4.41 | 0.33 | |
| Tangible Book Value Per Share | 22.77 | 23.39 | 12.43 | 4.14 | 0.98 | (33.2) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.